Abstract
Post-stroke muscle spasticity affects 37% of stroke survivors and disables self-supporting life management and ability to work. Current muscle relaxants are of limited efficiency (less than 40%) and cause serious neurological and cardiovascular side effects due to targeting the nervous system. We have developed a new-generation anti-spastic oral drug candidate, MPH-220, which directly and selectively inhibits fast skeletal myosin 2 isoforms. Brain-damage induced spastic animals showed drastic improvement in gait disorders upon oral MPH-220 treatment in different disease animal models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
